Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III bapineuzumab versus placebo in ApoE e4 non-carriers with mild to moderate Alzheimer's disease
2007-005994-79Phase 3Terminated
- Sponsor
- Wyeth
- Start
- Feb 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bapineuzumab in Alzheimer's disease (AD), sponsored by Wyeth. Started Feb 2008; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2007-005994-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005994-79.